Literature DB >> 15668979

Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.

Nikunj K Patel1, Martin Bunnage, Puneet Plaha, Clive N Svendsen, Peter Heywood, Steven S Gill.   

Abstract

We have shown previously that intraparenchymal infusion of glial cell line-derived neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson's disease patients is safe and may represent a new treatment option. Here, we report a continuation of this phase I study. After 2 years of continual GDNF infusion, there were no serious clinical side effects and no significant detrimental effects on cognition. Patients showed a 57% and 63% improvement in their off-medication motor and activities of daily living subscores of the Unified Parkinson's Disease Rating Scale, respectively, and health-related quality-of-life measures (Parkinson's Disease Questionnaire-39 and Short Form-36) showed general improvement over time.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15668979     DOI： 10.1002/ana.20374

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  97 in total

Review 1.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

2.  Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.

Authors:  David B O'Sullivan; Patrick T Harrison; Aideen M Sullivan
Journal:  J Neural Transm (Vienna)       Date:  2010-03-27       Impact factor: 3.575

Review 3.  Real-time imaging and quantification of brain delivery of liposomes.

Authors:  Michal T Krauze; John Forsayeth; John W Park; Krystof S Bankiewicz
Journal:  Pharm Res       Date:  2006-09-14       Impact factor: 4.200

4.  Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

Authors:  Jodi L McBride; Shilpa Ramaswamy; Mehdi Gasmi; Raymond T Bartus; Christopher D Herzog; Eugene P Brandon; Lili Zhou; Mark R Pitzer; Elizabeth M Berry-Kravis; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

Review 5.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

6.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 7.  Ethical issues in clinical neuroscience research: a patient's perspective.

Authors:  Perry D Cohen; Linda Herman; Sheryl Jedlinski; Peggy Willocks; Paula Wittekind
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 8.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

9.  GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors.

Authors:  Catarina A R V Gomes; Patrícia F Simões; Paula M Canas; César Quiroz; Ana M Sebastião; Sergi Ferré; Rodrigo A Cunha; Joaquim A Ribeiro
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

Review 10.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.